A Study of FT 2102 in Participants With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

Conditions:   Cohort 1a and 1b: Glioma;   Cohort 1a and 1b: Glioblastoma Multiforme;   Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas);   Cohort 3a and 3b: Chondrosarcoma;   Cohort 4a and  4b: Intrahepatic Cholangiocarcinoma;   Cohort 5a: Other Solid Tumors With IDH1 Mutations Interventions:   Drug: FT-2102;   Drug: Azacitidine;   Biological: Nivolumab;   Drug: Gemcitabine and Cisplatin Sponsor:   Forma Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials